2013-06332. Manufacturer of Controlled Substances; Notice of Application: Morton Grove Pharmaceuticals  

  • Start Preamble

    Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on December 14, 2012, Morton Grove Pharmaceuticals, 6451 Main Street, Morton Grove, Illinois 60053-2633, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Gamma Hydroxybutyric Acid (2010), a basic class of controlled substance listed in schedule I.

    The company plans to manufacture the listed controlled substance for distribution to its customers.

    Any other such applicant, and any person who is presently registered with DEA to manufacture such substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

    Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than May 20, 2013.

    Start Signature

    Dated: March 12, 2013.

    Joseph T. Rannazzisi,

    Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

    End Signature End Preamble

    [FR Doc. 2013-06332 Filed 3-19-13; 8:45 am]

    BILLING CODE 4410-09-P

Document Information

Published:
03/20/2013
Department:
Drug Enforcement Administration
Entry Type:
Notice
Document Number:
2013-06332
Pages:
17231-17231 (1 pages)
PDF File:
2013-06332.pdf